- Home
- CAC vs DNTH Comparison
CAC vs DNTH Comparison
Compare CAC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- DNTH
- Stock Information
- Founded
- CAC 1875
- DNTH 2015
- Country
- CAC United States
- DNTH United States
- Employees
- CAC N/A
- DNTH N/A
- Industry
- CAC Major Banks
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- CAC Finance
- DNTH Health Care
- Exchange
- CAC Nasdaq
- DNTH Nasdaq
- Market Cap
- CAC 629.3M
- DNTH 606.2M
- IPO Year
- CAC 1997
- DNTH N/A
- Fundamental
- Price
- CAC $37.32
- DNTH $18.76
- Analyst Decision
- CAC Buy
- DNTH Strong Buy
- Analyst Count
- CAC 3
- DNTH 8
- Target Price
- CAC $48.00
- DNTH $53.00
- AVG Volume (30 Days)
- CAC 81.5K
- DNTH 322.3K
- Earning Date
- CAC 07-29-2025
- DNTH 08-07-2025
- Dividend Yield
- CAC 4.48%
- DNTH N/A
- EPS Growth
- CAC 4.76
- DNTH N/A
- EPS
- CAC 3.11
- DNTH N/A
- Revenue
- CAC $197,501,000.00
- DNTH $4,854,000.00
- Revenue This Year
- CAC $40.83
- DNTH N/A
- Revenue Next Year
- CAC $5.29
- DNTH N/A
- P/E Ratio
- CAC $12.04
- DNTH N/A
- Revenue Growth
- CAC 21.74
- DNTH 17.87
- 52 Week Low
- CAC $34.53
- DNTH $13.37
- 52 Week High
- CAC $50.07
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- CAC 37.72
- DNTH 40.67
- Support Level
- CAC $36.61
- DNTH $20.00
- Resistance Level
- CAC $37.80
- DNTH $22.14
- Average True Range (ATR)
- CAC 1.28
- DNTH 1.46
- MACD
- CAC -0.37
- DNTH -0.33
- Stochastic Oscillator
- CAC 15.76
- DNTH 12.57
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.